Kim L R Brouwer
Overview
Explore the profile of Kim L R Brouwer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
168
Citations
3911
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hossain M, Mayo A, Ghoshal A, Taft-Benz S, Anderson E, Morales N, et al.
bioRxiv
. 2025 Jan;
PMID: 39868137
RA-0002034 () is a potent covalent inhibitor targeting the alphavirus nsP2 cysteine protease. The species-dependent pharmacokinetics and metabolism of were investigated to evaluate its therapeutic potential. Pharmacokinetic profiling revealed rapid...
2.
Yang F, Medik Y, Li L, Tian X, Fu D, Brouwer K, et al.
Small
. 2025 Jan;
21(6):e2405033.
PMID: 39790083
No abstract available.
3.
Tiley J, Beaudoin J, Derebail V, Murphy W, Park C, Veeder J, et al.
Br J Clin Pharmacol
. 2024 Sep;
91(2):353-364.
PMID: 39317666
Aims: Serum, liver and urinary bile acids are increased, and hepatic transport protein levels are decreased in a non-clinical model of polycystic kidney disease. Similar changes in patients with autosomal...
4.
Hartauer M, Murphy W, Brouwer K, Southall R, Neuhoff S
CPT Pharmacometrics Syst Pharmacol
. 2024 Jun;
13(9):1513-1527.
PMID: 38898552
OATP1B facilitates the uptake of xenobiotics into hepatocytes and is a prominent target for drug-drug interactions (DDIs). Reduced systemic exposure of OATP1B substrates has been reported following multiple-dose rifampicin; one...
5.
Vujic E, Ferguson S, Brouwer K
Toxicol Sci
. 2024 May;
200(2):213-227.
PMID: 38724241
Per- and polyfluoroalkyl substances (PFAS) have become internationally recognized over the past three decades as persistent organic pollutants used in the production of various consumer and industrial goods. Research efforts...
6.
Murphy W, Diehl A, Loop M, Fu D, Guy C, Abdelmalek M, et al.
Hepatol Commun
. 2024 Feb;
8(3).
PMID: 38381537
Background: NAFLD is highly prevalent with limited treatment options. Bile acids (BAs) increase in the systemic circulation and liver during NAFLD progression. Changes in plasma membrane localization and zonal distribution...
7.
Adiwidjaja J, Spires J, Brouwer K
Pharm Res
. 2024 Feb;
41(3):441-462.
PMID: 38351228
Purpose: This study was designed to verify a virtual population representing patients with nonalcoholic fatty liver disease (NAFLD) to support the implementation of a physiologically based pharmacokinetic (PBPK) modeling approach...
8.
Galetin A, Brouwer K, Tweedie D, Yoshida K, Sjostedt N, Aleksunes L, et al.
Nat Rev Drug Discov
. 2024 Jan;
23(4):255-280.
PMID: 38267543
The effect of membrane transporters on drug disposition, efficacy and safety is now well recognized. Since the initial publication from the International Transporter Consortium, significant progress has been made in...
9.
Saran C, Brouwer K
Toxicol Pathol
. 2023 Nov;
51(7-8):405-413.
PMID: 37982363
Drug-induced liver injury (DILI) remains a major concern in drug development from a patient safety perspective because it is the leading cause of acute liver failure. One mechanism of DILI...
10.
Jeong A, Pastor C, Brouwer K
Pharm Res
. 2023 Jun;
40(11):2513-2523.
PMID: 37349653
Background: Understanding the impact of altered hepatic uptake and/or efflux on the hepatobiliary disposition of the imaging agents [Tc]Mebrofenin (MEB) and [Gd]Gadobenate dimeglumine (BOPTA) is important for proper estimation of...